Inactivation of Apc in the mouse prostate causes prostate carcinoma

被引:75
作者
Bruxvoort, Katia J.
Charbonneau, Holli M.
Giambernardi, Troy A.
Goolsby, James C.
Qian, Chao-Nan
Zylstra, Cassandra R.
Robinson, Daniel R.
Roy-Burman, Pradip
Shaw, Aubie K.
Buckner-Berghuis, Bree D.
Sigler, Robert E.
Resau, James H.
Sullivan, Ruth
Bushman, Wade
Williams, Bart O.
机构
[1] Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, Grand Rapids, MI 49503 USA
[2] Van Andel Res Inst, Lab Analyt Cellular & Mol Microscopy, Grand Rapids, MI 49503 USA
[3] Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI 49503 USA
[4] Univ So Calif, Los Angeles, CA USA
[5] Univ Wisconsin, Div Urol, Madison, WI USA
[6] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA
[7] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
关键词
D O I
10.1158/0008-5472.CAN-06-3028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Alterations of the Wnt/beta-catenin signaling pathway are positively associated with the development and progression of human cancer, including carcinoma of the prostate. To determine the role of activated Wnt/beta-catenin signaling in mouse prostate carcinogenesis, we created a mouse prostate tumor model using probasin-Cre-mediated deletion of Apc. Prostate tumors induced by the deletion of Apc have elevated levels of beta-catenin protein and are highly proliferative. Tumor formation is fully penetrant and follows a consistent pattern of progression. Hyperplasia is observed as early as 4.5 weeks of age, and adenocarcinoma is observed by 7 months. Continued tumor growth usually necessitated sacrifice between 12 and 15 months of age. Despite the high proliferation rate, we have not observed metastasis of these tumors to the lymph nodes or other organs. Surgical castration of 6-week-old mice inhibited tumor formation, and castration of mice with more advanced tumors resulted in the partial regression of specific prostate glands. However, significant areas of carcinoma remained 2 months postcastration, suggesting that tumors induced by Ape loss of function are capable of growth under conditions of androgen depletion. We conclude that the prostate-specific deletion of Apc and the increased expression of beta-catenin associated with prostate carcinoma suggests a role for beta-catenin in prostate cancer and offers an appropriate animal model to investigate the interaction of Writ signaling with other genetic and epigenetic signals in prostate carcinogenesis.
引用
收藏
页码:2490 / 2496
页数:7
相关论文
共 49 条
  • [1] Abate-Shen C, 2003, CANCER RES, V63, P3886
  • [2] Molecular genetics of prostate cancer
    Abate-Shen, C
    Shen, MM
    [J]. GENES & DEVELOPMENT, 2000, 14 (19) : 2410 - 2434
  • [3] Abate-Shen Cory, 2002, Trends Genet, V18, pS1, DOI 10.1016/S0168-9525(02)02683-5
  • [4] Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation
    Bierie, B
    Nozawa, M
    Renou, JP
    Shillingford, JM
    Morgan, F
    Oka, T
    Taketo, MM
    Cardiff, RD
    Miyoshi, K
    Wagner, KU
    Robinson, GW
    Hennighausen, L
    [J]. ONCOGENE, 2003, 22 (25) : 3875 - 3887
  • [5] SOMATIC ALLELIC LOSS AT THE DCC, APC, NM23-H1 AND P53 TUMOR-SUPPRESSOR GENE LOCI IN HUMAN PROSTATIC-CARCINOMA
    BREWSTER, SF
    BROWNE, S
    BROWN, KW
    [J]. JOURNAL OF UROLOGY, 1994, 151 (04) : 1073 - 1077
  • [6] Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma -: Potential pathogenetic and prognostic implications
    Chen, GP
    Shukeir, N
    Potti, A
    Sircar, K
    Aprikian, A
    Goltzman, D
    Rabbani, SA
    [J]. CANCER, 2004, 101 (06) : 1345 - 1356
  • [7] Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO
  • [8] 2-W
  • [9] Recent progress in hormonal therapy for advanced prostate cancer
    Daskivich, Timothy J.
    Oh, William K.
    [J]. CURRENT OPINION IN UROLOGY, 2006, 16 (03) : 173 - 178
  • [10] Prevalent mutations in prostate cancer
    Dong, JT
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 97 (03) : 433 - 447